BMEA241115C17500
- 0.34
- 0.000.00%
Biomea Fusion Newsroom
H.C. Wainwright Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $40
Biomea Fusion Analyst Ratings
EF Hutton Initiates Coverage On Biomea Fusion With Buy Rating, Announces Price Target of $128
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $10
Scotiabank Maintains Biomea Fusion(BMEA.US) With Buy Rating, Raises Target Price to $41
A Quick Look at Today's Ratings for Biomea Fusion(BMEA.US), With a Forecast Between $10 to $60
Biomea Upgraded by Analysts After FDA Lifts Clinical Hold
Biomea Fusion Is Maintained at Equal-Weight by Barclays
Truist Securities Upgrades Biomea Fusion to Buy, Maintains Price Target to $54
A Quick Look at Today's Ratings for Biomea Fusion(BMEA.US), With a Forecast Between $9 to $60
Analysts Offer Insights on Healthcare Companies: Adverum Biotechnologies (ADVM), Biomea Fusion (BMEA) and Travere Therapeutics (TVTX)
Piper Sandler Remains a Buy on Biomea Fusion (BMEA)
Buy Rating Affirmed for Biomea Fusion With Promising BMF-219 Clinical and Regulatory Developments
Biomea Fusion Analyst Ratings
Rodman & Renshaw Upgrades Biomea Fusion to Buy, Announces $18 Price Target
Balanced Outlook With a Hold Rating for Biomea Fusion Amidst Upcoming Milestones and Clinical Developments
Truist Financial Maintains Biomea Fusion(BMEA.US) With Hold Rating
Truist Financial Issues a Hold Rating on Biomea Fusion (BMEA)
Biomea Fusion Analyst Ratings
Biomea Fusion Initiated at Overweight by Capital One